2020 Conference on Retroviruses and Opportunistic Infections

March 8-11, 2020; Boston, Massachusetts
Get up to date on the latest HIV data with rapid Capsule Summaries, video highlights, downloadable slidesets, on-demand audio, and expert analysis covering key studies from Boston.

Share

Program Content

10 Capsule Summary Slidesets

Activities

Rapid ART in Youth
Rapid and Sustained Viral Suppression Following Initiation of ART Within 72 Hrs of Diagnosis in Young Persons With HIV in New Orleans
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2020

IMPAACT 2010
IMPAACT 2010: Viral Suppression Rates at Delivery Significantly Higher With DTG Plus FTC/TAF or FTC/TDF vs EFV/FTC/TDF Initiation During Pregnancy in ART-Naive Women
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2020

ATLAS-2M: Wk 48 Results
ATLAS-2M: Switch to Long-Acting Injectable Cabotegravir + Rilpivirine Every 2 Mos Is Noninferior to Switch to Monthly Injections in Virologically Suppressed Patients at Wk 48
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 10, 2020

BIC/FTC/TAF in Aging PWH
BIC/FTC/TAF Efficacy and Safety Similar to DTG-Based 3-Drug Regimens at Wk 144 in ART-Naive Patients Aged 50 Yrs or Older
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2020

FLAIR: Week 96 Results
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued Oral DTG/ABC/3TC at Wk 96
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2020

GEMINI-1 & -2: Wk 96 CVW
GEMINI-1 and -2: Rates of Confirmed Virologic Withdrawal at Wk 96 Similar With DTG Plus 3TC vs DTG Plus FTC/TDF in Treatment-Naive Patients
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2020

ISL + DOR Metabolic Study
DRIVE2Simplify Exploratory Analysis: Metabolic Outcomes With Islatravir Plus DOR vs DOR/3TC/TDF in ART-Naive Adults at Wk 48
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2020

ADVANCE: Diabetes and CVD
ADVANCE: Risk of Cardiovascular Disease and Diabetes in Treatment-Naive Patients Initiating Dolutegravir- or Efavirenz-Based ART
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2020

<i>CYP2B6</i> and Weight on EFV
ADVANCE Post Hoc Analysis: CYP2B6 Genotype Associated With Differential Weight Gain in ART-Naive Patients Initiating Efavirenz-Based ART in South Africa
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2020

DISCOVER 96-Wks
DISCOVER: More Favorable Renal and Bone Outcomes With FTC/TAF vs FTC/TDF for HIV PrEP Through 96 Wks
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 15, 2020

Activities

CROI 2020 Hot Topics
A Preview of CROI 2020: My Take on Hot Topics
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: March 06, 2020

ART Weight Gain Pregnancy
Potential Implications of Emerging Data on ART Efficacy, Safety, and Weight Gain During and After Pregnancy
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: April 21, 2020

ART and Weight Gain
My Take on Recent Data on the Metabolic Implications of Weight Gain Associated With ART
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: April 14, 2020

CROI 2020
Clinical Impact of New Data From CROI 2020
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 31, 2020

7 Capsule Summary Slidesets

Activities

HIV Diagnoses in France
Dat’AIDS Cohort: Annual HIV Diagnoses in France Decreased by More Than One Third Between 2013 and 2018
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 15, 2020

Expires: March 14, 2021

EU Progress: 90-90-90
Updated 2016 Analysis of Progress Toward UNAIDS 90-90-90 Goal in PWH From 11 European Union Countries
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 15, 2020

Expires: March 14, 2021

TAIPAN: HIV TasP
TAIPAN Longitudinal Cohort Study: Significant Correlations Between Community Viremia and HIV Incidence in Gay and Bisexual Men in Australia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 18, 2020

Expires: March 17, 2021

ARV Resistance in Spain
Low Prevalence of Transmitted ARV Resistance in CoRIS Cohort of ART-Naive PWH In Spain From 2007-2018
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 18, 2020

Expires: March 17, 2021

EuResist: 4-Class Resistance
Low and Declining Rate of 4-Class ARV Resistance Among Treatment-Experienced Patients in the EuResist Database
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 15, 2020

Expires: March 14, 2021

HIV/HCV: DAA Therapy
DAA Treatment for HCV Reduced Healthcare Service Utilization in a Population of Individuals With HIV/HCV Coinfection in Canada
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2020

Expires: March 16, 2021

France: HIV/HCV in MSM
FHDH-ANRS CO4 Cohort: HCV Incidence in MSM With HIV Declined Following Access to HCV DAA Therapy in France
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2020

Expires: March 16, 2021

Activities

Long-Acting ART
Why I Am Excited About Long-Acting ART and Why I Think It Is Here to Stay!
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: April 06, 2020

Expires: April 05, 2021

HIV and SARS-CoV-2
HIV and SARS-CoV-2: What Are the Risks?
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: April 01, 2020

Expires: March 31, 2021

Expert Analysis
Expert Analysis: Insights for International Clinicians on New Data From CROI 2020
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 21, 2020

Expires: April 20, 2021

Activities

CROI 2020: Weight Gain With ART
Weight Gain During HIV Treatment and the Latest in HIV Prevention
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2020

Faculty

cover img faculity

Monica Gandhi, MD, MPH

Professor of Medicine
Associate Chief, Division of HIV, Infectious Diseases and Global Medicine
Director, Center for AIDS Research
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco 
San Francisco, California

cover img faculity

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

cover img faculity

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

cover img faculity

Josep M. Llibre, MD, PhD

Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain

cover img faculity

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

cover img faculity

Laura Waters, FRCP, MD

Consultant Physician, HIV/GU Medicine
Mortimer Market Centre
CNWL NHS Trust
London, United Kingdom

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Gilead

Merck & Co., Inc.

ViiV Healthcare